BIORA THERAPEUTICS, INC.
DelistedCIK 1580063fmd_0DH46BEWR8749EYZVYKBBJGCBZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2024, 23 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Total revenues | 144 | 74 | 61 | 12 | 0 |
| Cost of revenue | 100 | 0 | 0 | – | – |
| Gross profit | 43 | 0 | 1 | – | – |
| Realized investment gains (losses) | – | – | 0 | 6 | (3) |
| Research and development | 63 | 48 | 46 | 24 | 30 |
| Selling, general and administrative | 120 | 60 | 73 | 38 | 37 |
| Total operating expenses | 184 | 108 | 119 | 62 | 67 |
| Operating income | (140) | (108) | (118) | (62) | (67) |
| Interest expense | 9 | 10 | 13 | 11 | 10 |
| Other non-operating income (expense) | 1 | (25) | 6 | 3 | (65) |
| Income before taxes | (149) | (143) | (179) | (49) | (124) |
| Income tax expense | (1) | (38) | (0) | (0) | (0) |
| Net income from continuing operations | (148) | (105) | (179) | (49) | (124) |
| Net income | (148) | (193) | (247) | (38) | (124) |
| Net income to common shareholders | – | (193) | (247) | – | – |